Analyst Andy Chen of Wolfe Research maintained a Buy rating on Dianthus Therapeutics, with a price target of $98.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andy Chen has given his Buy rating due to a combination of factors tied to Dianthus’s lead asset, claseprubart, and its broader pipeline. He expects claseprubart’s mechanism of complement inhibition to translate into meaningful efficacy across gMG, CIDP, and MMN, with performance potentially comparable to empasiprubart, while offering a more favorable safety profile than existing C5 and C2 inhibitors.
Andy also highlights the convenience of an autoinjectable formulation, which should support uptake even as a later entrant. In addition, he sees underappreciated value in the BDCA2 + BAFF/APRIL bifunctional program and views upcoming Biogen litifilimab data as a key external catalyst, estimating a high probability of success that could validate the mechanism and enhance the perceived competitiveness of Dianthus’s approach.
In another report released on April 1, Wells Fargo also maintained a Buy rating on the stock with a $135.00 price target.